Solventum offers a credible medical technology turnaround supported by durable clinical franchises and portfolio simplification, but weak cash conversion, substantial leverage, and separation execution risks constrain near-term upside.
Hold-rated reports
904 tickers rated HoldDevon could unlock higher per-share cash flow through Coterra synergies, Permian efficiency and asset-sale-funded buybacks, but commodity volatility, heavy reinvestment and integration risk constrain its valuation upside.
Genworth's valuable Enact stake and aggressive share repurchases offer potential upside, but persistent long-term care insurance losses and uncertain legacy liabilities constrain the investment case.
Flutter offers substantial recovery potential through FanDuel's market position and an unusually low historical revenue valuation, but regulatory disruption, weak operating leverage, and elevated debt threaten shareholder returns.
ITT offers durable engineered-industrial franchises, aerospace demand exposure, and SPX FLOW synergy potential, but elevated acquisition leverage and demanding valuation limit its near-term margin of safety.
Host Hotels & Resorts combines scarce luxury hotel assets, improving RevPAR, and strong cash generation, but its elevated historical FFO valuation and sensitivity to travel cycles limit the margin of safety.
Liberty Global's discounted investment portfolio, substantial corporate liquidity and planned Ziggo Group spin-off offer value-unlock potential, but high telecommunications leverage and weak recurring cash generation threaten that upside.
Fortis offers durable regulated utility earnings and dividend growth backed by a major transmission investment pipeline, but premium valuation, heavy capital spending, and financing dilution constrain its prospective shareholder returns.
Knife River's locally advantaged aggregates assets and operational improvement initiatives offer cyclical recovery potential, but weak contracting margins, capital-intensive growth and elevated leverage constrain shareholder returns.
Sotera Health combines essential sterilization services, strong operating margins, and improving leverage with a credible earnings growth outlook, but EO litigation exposure and substantial capital requirements constrain its risk-adjusted upside.
Supermicro offers exceptional exposure to AI infrastructure growth at low earnings multiples, but persistent cash consumption, shareholder dilution, and governance risks threaten the durability of per-share value creation.
Mirum's expanding rare-disease drug portfolio and late-stage pipeline support sustained commercial growth, but substantial dilution, negative recent cash flow, and demanding valuation limit near-term investment appeal.